Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
BRIDGEWATER, N.J., April 26, 2017 -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that it will release its first quarter 2017 financial results on Wednesday, May 3, 2017.
Will Lewis, president and chief executive officer, will host a conference call for investors beginning at 8:30 a.m. ET on Wednesday, May 3, 2017 to discuss the financial results and provide a business update.
Shareholders and other interested parties may participate in the conference call by dialing (844) 707-0669 (domestic) or (703) 639-1223 (international) and referencing conference ID number 3999935. The call will also be webcast live on the internet on the company's website at www.insmed.com.
A replay of the conference call will be accessible approximately two hours after its completion through May 17, 2017 by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international) and referencing conference ID number 3999935. A webcast of the call will also be archived for 90 days under the Investor Relations section of the company's website at www.insmed.com.
About Insmed
Insmed Incorporated is a global biopharmaceutical company focused on the unmet needs of patients with rare diseases. The company is advancing a global phase 3 clinical study of ARIKAYCE® (liposomal amikacin for inhalation) for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC), a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. There are currently no approved inhaled products specifically indicated for the treatment of refractory NTM lung infections caused by MAC in the United States or European Union (EU). Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of DPP1 with therapeutic potential in non-CF bronchiectasis, and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare disorders, including pulmonary arterial hypertension (PAH). For more information, visit www.insmed.com.
"Insmed" and "ARIKAYCE" are the company's trademarks. All other trademarks, trade names or service marks appearing in this press release are the property of their respective owners.
Investor Contact: Laura Perry or Heather Savelle Argot Partners 212-600-1902 [email protected] [email protected]
